Hesperidin may improve depressive symptoms by binding NLRP3 and influencing the pyroptosis pathway in a rat model

Hui Cao,Dong Yang,Kechao Nie,Ruoheng Lin,Luqi Peng,Xuhui Zhou,Mei Zhang,Ying Zeng,Lini Liu,Wei Huang
DOI: https://doi.org/10.1016/j.ejphar.2023.175670
IF: 5.195
2023-05-11
European Journal of Pharmacology
Abstract:Objective Major depressive disorder (MDD) is a debilitating psychiatric disorder which is common and endangers human physical and mental health. Studies have shown that hesperidin could improve the symptoms of depression with unclear mechanisms. Method In this study, hesperidin was administered to chronic unpredictable mild stress (CUMS) depressed mice before behavioral test, network pharmacology analysis, RNA expression microarray analysis, pathway validation and molecular docking experiments. Results we found that hesperidin intervention could significantly improve the depressive symptoms and downregulate the expression level of pyroptosis pathway including caspase 1 (Casp1), interleukin 18 (IL18), interleukin-1β (IL-1β) and NOD-like receptor thermal protein domain associated protein 3 (NLRP3). In addition, we found that hesperidin could possibly bind to NLRP3. Conclusions Our study demonstrated that hesperidin had huge potential as anti-depressive neuroprotectant, and may play a role in treating MDD by regulating NLRP3-mediated pyroptosis.
pharmacology & pharmacy
What problem does this paper attempt to address?